-+ 0.00%
-+ 0.00%
-+ 0.00%

HC Wainwright & Co. Maintains Buy on Genmab, Lowers Price Target to $38

Benzinga·04/30/2026 10:22:43
Listen to the news
HC Wainwright & Co. analyst Raghuram Selvaraju maintains Genmab (NASDAQ:GMAB) with a Buy and lowers the price target from $40 to $38.